Lurbinectedin is a chemotherapy drug used to treat small cell lung cancer (SCLC) and advanced solid tumors. It works by inhibiting RNA polymerase II, which is an enzyme that plays a critical role in the transcription process of DNA to RNA. This inhibition leads to the accumulation of DNA damage and ultimately cell death. [2]

In 2020, the U.S. Food and Drug Administration (FDA) approved lurbinectedin under the brand name Zepzelca for the treatment of metastatic SCLC. It is indicated for patients who have previously received chemotherapy. [2]

Clinical trials have shown that lurbinectedin has significant antitumor activity in various types of cancer, including ovarian, breast, and lung cancers. However, further studies are needed to fully understand its potential in treating these cancers. [1]

Lurbinectedin is administered intravenously by a healthcare professional. The most common side effects include fatigue, nausea, vomiting, decreased appetite, constipation, and diarrhea. Patients should inform their doctor if they experience any side effects or have any concerns about the treatment. [3]

In conclusion, lurbinectedin is a chemotherapy drug used to treat SCLC and advanced solid tumors by inhibiting RNA polymerase II. It has been approved by the FDA under the brand name Zepzelca for the treatment of metastatic SCLC. Although it has shown potential in treating other types of cancer, further studies are needed. Patients should be aware of the potential side effects and inform their doctor of any concerns. [1][2][3]

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.cancer.gov/about-cancer/treatment/drugs/lurbinectedin
[3] https://medlineplus.gov/druginfo/meds/a620049.html